番茄社区app

Purpose

Sacituzumab govitecan (SG) is approved for the treatment of metastatic triple-negative breast cancer (mTNBC). We report the real-world clinical effectiveness and toxicity data of SG in patients with mTNBC.

Methods

A multi-institution retrospective study of patients with mTNBC treated with SG from January 2021 to May 2023 was conducted. Demographic and clinicopathologic variables were collected. Univariate and multivariate Cox regression models were used for survival analysis.

Results

A total of 115 patients were included. The median age at SG initiation was 60 years (range 31-85). All patients were female; 73 (63.5%) were white and 31 (27.0%) were Black. The median number of previous therapies in the metastatic setting was two (range 0-8). Sixty-one patients (56.0%) had primary refractory disease. Median relative dose intensity was 92% (range 33-100%). Grade 3 or higher adverse events (AEs) were seen in 50.9% of patients, which included neutropenia (35.7%), anemia (27.0%), vomiting (16.5%), fatigue (8.7%), and diarrhea (7.0%). Dose reductions and treatment discontinuation due to AEs were required in 51.3% and 13.2% of patients, respectively. The objective response rate (ORR) was 27.8%. Median overall survival was 9.6 months (95% CI 7.8-12.9) and median progression-free survival (PFS) was 4.8 months (95% CI 3.6- 5.9). In patients with human epidermal growth factor receptor 2 (HER2)–low mTNBC who received trastuzumab deruxtecan (T-DXd) after SG, the ORR to T-DXd was 34.8% and median PFS was 7 months (95% CI 4.6-10.1).

Conclusion

In a real-world cohort of heavily pretreated patients with mTNBC, SG retains its clinical activity. In a subgroup with HER2-low disease, T-DXd continues to demonstrate promising clinical activity after SG, supporting the use of sequential antibody-drug conjugates in this population.

Read an interview about the study here and expert commentary about it here.